Medicare Negotiation List Surprises Highlight The Importance Of Current Spending Data
Some drugs recorded significant increases in Medicare gross spending between the periods covered by publicly available data and what CMS had access to internally, which contributed to their unexpected presence on the list.
You may also be interested in...
As FDA clears new COVID vaccines, the Regeneron deal is a reminder of the politics of drug pricing. Sen. Sanders touts the agreement, which attaches product price caps to funding for clinical development, and he allows the confirmation effort for the NIH director nominee to proceed.
The first 10 drugs picked for price negotiation in the US Medicare program will all be unwilling trailblazers. But the position of Abbvie’s Imbruvica stands out as unique in several important ways.
The inaugural class of drugs subject to the new US Medicare price negotiation process includes four antidiabetics. But none are from the biggest and fastest growing class – thanks to few technicalities in how the law works.